Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

Annual out-of-pocket treatment costs for multiple sclerosis increased by 125% from 2002 to 2021 in the US, driven mainly by ...

An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis have won ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...

As the multiple sclerosis (MS) population ages, managing the condition can bring new challenges. For one woman, working closely with her doctor, exploring treatment options, and finding the right ...

Many symptoms of MS are the same as those of other conditions. If you are concerned that you may have MS, make an appointment with your primary care provider. They will discuss your concerns and do a ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio March is Multiple Sclerosis Awareness ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...